A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain

Add time:08/19/2019    Source:sciencedirect.com

AimsFirst proof to show that (−)-deprenyl/selegiline (DEP), the first selective inhibitor of MAO-B, later identified as the first β-phenylethylamine (PEA)-derived synthetic catecholaminergic activity enhancer (CAE) substance and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP), the tryptamine-derived presently known most potent, selective, synthetic enhancer substance, are specific markers of unknown enhancer-sensitive brain regulations.

We also recommend Trading Suppliers and Manufacturers of substance P, Pro(9)-Met(O2)(11)- (cas 110880-54-1). Pls Click Website Link as below: cas 110880-54-1 suppliers

Prev:Localization of dynorphin B-like and alpha-neoendorphin-like immunoreactivities in the guinea pig organ of Corti
Next:Original studyThe anti-arrhythmic effect of d-Ala 2, Leu 5, Arg 6-enkephalin and its possible mechanism)